TrialSignal
Clinical trial intelligence report
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 22, 2026
NCT ID
NCT07116928
Status
NOT_YET_RECRUITING
Phase
PHASE4
Sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Executive brief
Investment-Ready Snapshot
This study aims to investigate the impact of adding Ganagliflozin tablets to the current background therapy on preventing the progression of kidney disease in subjects with type 2 diabetes and chronic kidney disease. The efficacy and safety will be evaluated by comparing the effects of Ganagliflozin tablets and placebo tablets added to the current background treatment over 120 weeks
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT07116928
Indication
T2DM (Type 2 Diabetes Mellitus)
Modality
small molecule
Target
ganagliflozin, Placebo
Intervention
ganagliflozin, Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.